Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.
Bradley
Deborah A
DA
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-0946, USA.
Hussain
Maha
M
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D002117:Calcitriol / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D003603:Cytotoxins / Q000627:therapeutic use*; D000077143:Docetaxel; D034261:Epothilones / Q000627:therapeutic use; D005663:Furans / Q000627:therapeutic use; D006801:Humans; D007659:Ketones / Q000627:therapeutic use; D008297:Male; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D011799:Quinazolines / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D000095662:Polyether Polyketides
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D001549:Benzamides; D002117:Calcitriol; D019496:Cancer Vaccines; D003603:Cytotoxins; D000077143:Docetaxel; D034261:Epothilones; D005663:Furans; D007659:Ketones; D009944:Organoplatinum Compounds; D017239:Paclitaxel; D011799:Quinazolines; D043823:Taxoids; C081294:satraplatin; C508757:ispinesib; C490954:eribulin; D000095662:Polyether Polyketides